Core Insights - Ginkgo Bioworks has formed a strategic partnership with Inductive Bio and Tangible Scientific to enhance AI-driven drug discovery, making it more accessible across the industry [1][2] - The collaboration integrates Ginkgo Datapoints' rapid ADME profiling, Inductive Bio's model-driven chemistry design, and Tangible Scientific's compound management platform to streamline drug discovery processes [2][3] Group 1: Partnership Objectives - The partnership aims to transition from in-silico compound designs to validated experimental results in a single digital workflow, reducing synthesis cycles and overall drug discovery costs [2][3] - By coupling model-driven design with efficient logistics, the collaboration seeks to enable scientists to iterate quickly and utilize advanced digital tools for drug discovery [4][8] Group 2: Technological Integration - Ginkgo Datapoints provides high-quality ADME profiling services, including metrics like microsomal stability and permeability, benefiting from Boston's biopharma hub logistics [5][6] - Tangible Scientific's platform facilitates secure storage and rapid movement of compounds, allowing researchers to access Ginkgo's services directly from their digital environments [6][12] Group 3: Industry Context - The drug discovery process has evolved into a complex global logistics challenge, necessitating efficient coordination among various vendors and locations [3] - The partnership aligns with the FDA's goals for faster drug development timelines and increased use of AI tools in the industry [8] Group 4: Service Availability - The integrated services are currently available for pharmaceutical and biotech teams aiming to enhance ADMET optimization and reduce iteration times [9]